SenesTech, Inc.SNESEarnings & Financial Report
Nasdaq
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
SNES Q3 2025 Key Financial Metrics
Revenue
$690.0K
Gross Profit
$433.0K
Operating Profit
$-1.3M
Net Profit
$-1.3M
Gross Margin
62.8%
Operating Margin
-195.2%
Net Margin
-188.1%
YoY Growth
43.2%
EPS
$-0.28
Financial Flow
SenesTech, Inc. Q3 2025 Financial Summary
SenesTech, Inc. reported revenue of $690.0K for Q3 2025, with a net profit of $-1.3M (-188.1% margin). Cost of goods sold was $257.0K, operating expenses totaled $1.8M.
Key Financial Metrics
| Total Revenue | $690.0K |
|---|---|
| Net Profit | $-1.3M |
| Gross Margin | 62.8% |
| Operating Margin | -195.2% |
| Report Period | Q3 2025 |
SenesTech, Inc. Annual Revenue by Year
SenesTech, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.9M |
| 2023 | $1.2M |
| 2022 | $1.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $295000 | $415000 | $459000 | $482000 | $501000 | $485000 | $625000 | $690000 |
| YoY Growth | -0.7% | 78.1% | 50.5% | 33.9% | 69.8% | 16.9% | 36.2% | 43.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.3M | $5.5M | $4.0M | $4.4M | $3.3M | $3.6M | $10.4M | $14.6M |
| Liabilities | $942000 | $862000 | $923000 | $798000 | $767000 | $734000 | $3.4M | $3.3M |
| Equity | $6.4M | $4.6M | $3.1M | $3.7M | $2.5M | $2.9M | $7.0M | $11.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.0M | $-1.8M | $-1.6M | $-1.4M | $-1.2M | $-1.6M | $-1.1M | $-1.4M |